Characteristics of patients receiving a myeloablative conditioning regimen for an unrelated donor bone marrow or peripheral blood transplantation reported to the NMDP between 1990 and 2002, stratified by CCR5 genotype
| Patient characteristic . | CCR5 H1/H1, n (%) . | Others, n (%) . | P* . |
|---|---|---|---|
| Total number of patients | 163 | 1085 | |
| Age at transplantation, y | .084 | ||
| 10 or younger | 19 (12) | 70 (6) | |
| 10-19 | 11 (7) | 112 (10) | |
| 20-29 | 26 (16) | 174 (16) | |
| 30-39 | 43 (26) | 282 (26) | |
| 40-49 | 47 (29) | 284 (26) | |
| 50-59 | 17 (10) | 163 (15) | |
| Karnofsky score before transplantation | .919 | ||
| Less than 90 | 42 (26) | 270 (25) | |
| 90 or higher | 117 (72) | 783 (72) | |
| Missing | 4 (2) | 32 (3) | |
| Male sex | 100 (61) | 615 (57) | .261 |
| Disease | .267 | ||
| Acute leukemia | 39 (24) | 271 (25) | |
| Acute lymphoblastic leukemia | 36 (22) | 197 (18) | |
| Chronic lymphocytic leukemia | 58 (36) | 457 (42) | |
| Myelodysplastic syndrome | 30 (18) | 160 (15) | |
| Disease stage before transplantation | .218 | ||
| Early | 62 (38) | 506 (47) | |
| Intermediate | 48 (29) | 265 (24) | |
| Advanced | 42 (26) | 254 (23) | |
| Unknown | 11 (7) | 60 (6) | |
| Graft type | .713 | ||
| Bone marrow | 152 (93) | 1003 (92) | |
| Peripheral blood | 11 (7) | 82 (8) | |
| Donor/recipient sex match | .440 | ||
| Male/male | 65 (40) | 435 (40) | |
| Female/male | 35 (21) | 265 (24) | |
| Male/female | 35 (21) | 180 (17) | |
| Female/female | 28 (17) | 205 (18) | |
| Donor/recipient CMV match | .082 | ||
| Negative/negative | 68 (42) | 395 (36) | |
| Positive/negative | 49 (30) | 290 (27) | |
| Negative/positive | 16 (10) | 187 (17) | |
| Positive/positive | 28 (17) | 179 (17) | |
| Unknown | 2 (1) | 34 (3) | |
| Year of transplantation | .348 | ||
| 1990-1995 | 42 (28) | 337 (33) | |
| 1996-2000 | 89 (58) | 565 (55) | |
| 2001-2002 | 22 (14) | 122 (13) | |
| Conditioning regimen | .868 | ||
| Cy + TBI ± other | 121 (75) | 832 (77) | |
| Cy + Bu ± other | 5 (3) | 187 (17) | |
| TBI ± other | 33 (20) | 39 (4) | |
| Bu ± other | 2 (1) | 20 (2) | |
| Lpam ± other | 1 (1) | 7 (1) | |
| GVHD prophylaxis | .163 | ||
| T-cell depletion | 20 (12) | 184 (16) | |
| CSA + MTX ± other | 112 (69) | 654 (61) | |
| FK506 + MTX ± other | 20 (12) | 178 (16) | |
| Other | 11 (7) | 69 (6) |
| Patient characteristic . | CCR5 H1/H1, n (%) . | Others, n (%) . | P* . |
|---|---|---|---|
| Total number of patients | 163 | 1085 | |
| Age at transplantation, y | .084 | ||
| 10 or younger | 19 (12) | 70 (6) | |
| 10-19 | 11 (7) | 112 (10) | |
| 20-29 | 26 (16) | 174 (16) | |
| 30-39 | 43 (26) | 282 (26) | |
| 40-49 | 47 (29) | 284 (26) | |
| 50-59 | 17 (10) | 163 (15) | |
| Karnofsky score before transplantation | .919 | ||
| Less than 90 | 42 (26) | 270 (25) | |
| 90 or higher | 117 (72) | 783 (72) | |
| Missing | 4 (2) | 32 (3) | |
| Male sex | 100 (61) | 615 (57) | .261 |
| Disease | .267 | ||
| Acute leukemia | 39 (24) | 271 (25) | |
| Acute lymphoblastic leukemia | 36 (22) | 197 (18) | |
| Chronic lymphocytic leukemia | 58 (36) | 457 (42) | |
| Myelodysplastic syndrome | 30 (18) | 160 (15) | |
| Disease stage before transplantation | .218 | ||
| Early | 62 (38) | 506 (47) | |
| Intermediate | 48 (29) | 265 (24) | |
| Advanced | 42 (26) | 254 (23) | |
| Unknown | 11 (7) | 60 (6) | |
| Graft type | .713 | ||
| Bone marrow | 152 (93) | 1003 (92) | |
| Peripheral blood | 11 (7) | 82 (8) | |
| Donor/recipient sex match | .440 | ||
| Male/male | 65 (40) | 435 (40) | |
| Female/male | 35 (21) | 265 (24) | |
| Male/female | 35 (21) | 180 (17) | |
| Female/female | 28 (17) | 205 (18) | |
| Donor/recipient CMV match | .082 | ||
| Negative/negative | 68 (42) | 395 (36) | |
| Positive/negative | 49 (30) | 290 (27) | |
| Negative/positive | 16 (10) | 187 (17) | |
| Positive/positive | 28 (17) | 179 (17) | |
| Unknown | 2 (1) | 34 (3) | |
| Year of transplantation | .348 | ||
| 1990-1995 | 42 (28) | 337 (33) | |
| 1996-2000 | 89 (58) | 565 (55) | |
| 2001-2002 | 22 (14) | 122 (13) | |
| Conditioning regimen | .868 | ||
| Cy + TBI ± other | 121 (75) | 832 (77) | |
| Cy + Bu ± other | 5 (3) | 187 (17) | |
| TBI ± other | 33 (20) | 39 (4) | |
| Bu ± other | 2 (1) | 20 (2) | |
| Lpam ± other | 1 (1) | 7 (1) | |
| GVHD prophylaxis | .163 | ||
| T-cell depletion | 20 (12) | 184 (16) | |
| CSA + MTX ± other | 112 (69) | 654 (61) | |
| FK506 + MTX ± other | 20 (12) | 178 (16) | |
| Other | 11 (7) | 69 (6) |
Bu indicates busulfan; CMV, cytomegalovirus; Cy, cyclophosphamide; CSA, cyclosporine; FK506, tacrolimus; GVHD, graft-versus-host disease; Lpam, melphalan; MTX, methotrexate; and TBI, total body irradiation.
χ2 test of significance.